PubMed:32409150 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":27,"end":38},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T2","span":{"begin":42,"end":60},"obj":"CHEBI:5801;DG_20;CHEBI:5801"},{"id":"T3","span":{"begin":66,"end":78},"obj":"CHEBI:2955;DG_6;CHEBI:2955"},{"id":"T4","span":{"begin":82,"end":89},"obj":"UBERON:0000948"},{"id":"T5","span":{"begin":157,"end":164},"obj":"SP_7"},{"id":"T6","span":{"begin":177,"end":198},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T7","span":{"begin":202,"end":220},"obj":"CHEBI:5801;DG_20;CHEBI:5801"},{"id":"T8","span":{"begin":222,"end":233},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T9","span":{"begin":240,"end":252},"obj":"CHEBI:2955;DG_6;CHEBI:2955"},{"id":"T10","span":{"begin":282,"end":290},"obj":"SP_7"},{"id":"T11","span":{"begin":449,"end":456},"obj":"UBERON:0000948"},{"id":"T12","span":{"begin":496,"end":507},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T13","span":{"begin":512,"end":524},"obj":"CHEBI:2955;DG_6;CHEBI:2955"},{"id":"T14","span":{"begin":529,"end":540},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T15","span":{"begin":545,"end":556},"obj":"CHEBI:2676;CHEBI:2676"},{"id":"T16","span":{"begin":712,"end":722},"obj":"UBERON:0002405"},{"id":"T17","span":{"begin":766,"end":778},"obj":"CHEBI:2955;DG_6;CHEBI:2955"},{"id":"T18","span":{"begin":782,"end":793},"obj":"CHEBI:2676;CHEBI:2676"},{"id":"T19","span":{"begin":813,"end":824},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T20","span":{"begin":949,"end":954},"obj":"GO:0016265"},{"id":"T21","span":{"begin":981,"end":988},"obj":"UBERON:0000948"},{"id":"T22","span":{"begin":996,"end":1007},"obj":"UBERON:0002082"},{"id":"T23","span":{"begin":1033,"end":1040},"obj":"UBERON:0000948"},{"id":"T24","span":{"begin":1305,"end":1312},"obj":"UBERON:0000948"},{"id":"T25","span":{"begin":1328,"end":1340},"obj":"CHEBI:2955;DG_6;CHEBI:2955"},{"id":"T26","span":{"begin":1345,"end":1356},"obj":"CHEBI:2676;CHEBI:2676"},{"id":"T27","span":{"begin":1481,"end":1492},"obj":"CHEBI:3638;DG_10;CHEBI:3638"},{"id":"T28","span":{"begin":1497,"end":1509},"obj":"CHEBI:2955;DG_6;CHEBI:2955"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.\nBACKGROUND: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed.\nOBJECTIVE: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin.\nMETHODS: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged ≥18 years initiating azithromycin or amoxicillin for ≥5 days during chloroquine treatment. Patients had continuous insurance coverage ≥6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting.\nRESULTS: We identified two SVC/VA events among \u003e145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95).\nCONCLUSION: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions."}

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":712,"end":730},"obj":"Phenotype"},{"id":"T2","span":{"begin":974,"end":995},"obj":"Phenotype"},{"id":"T3","span":{"begin":996,"end":1019},"obj":"Phenotype"},{"id":"T4","span":{"begin":1564,"end":1575},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0031628"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0004308"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0011675"}],"text":"An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.\nBACKGROUND: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed.\nOBJECTIVE: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin.\nMETHODS: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged ≥18 years initiating azithromycin or amoxicillin for ≥5 days during chloroquine treatment. Patients had continuous insurance coverage ≥6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting.\nRESULTS: We identified two SVC/VA events among \u003e145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95).\nCONCLUSION: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions."}